These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 12102740)

  • 21. High steady-state levels of p53 are not a prerequisite for tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.
    Vierboom MP; Zwaveling S; Bos GMJ ; Ooms M; Krietemeijer GM; Melief CJ; Offringa R
    Cancer Res; 2000 Oct; 60(19):5508-13. PubMed ID: 11034095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenic targets for renal cell carcinoma immunotherapy.
    Vieweg J; Jackson A
    Expert Opin Biol Ther; 2004 Nov; 4(11):1791-801. PubMed ID: 15500407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer.
    Dannull J; Diener PA; Prikler L; Fürstenberger G; Cerny T; Schmid U; Ackermann DK; Groettrup M
    Cancer Res; 2000 Oct; 60(19):5522-8. PubMed ID: 11034097
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MHC class I status of tumours and design of immunotherapeutic strategies.
    Bubeník J; Vonka V
    Immunol Lett; 2003 Dec; 90(2-3):177-8. PubMed ID: 14687722
    [No Abstract]   [Full Text] [Related]  

  • 25. Teaching the immune system to fight cancer.
    Boon T
    Sci Am; 1993 Mar; 268(3):82-9. PubMed ID: 8316825
    [No Abstract]   [Full Text] [Related]  

  • 26. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
    Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
    Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy of cancer through targeting of the p53 tumor antigen.
    Zwaveling S; Van der Burg SH; Menon AG; Melief CJ; Offringa R
    Arch Immunol Ther Exp (Warsz); 2002; 50(5):297-305. PubMed ID: 12455863
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genes coding for antigens recognized on human tumors by autologous cytolytic T lymphocytes.
    Coulie P; Weynants P; Muller C; Lehmann F; Herman J; Baurain JF; Boon T
    Ann N Y Acad Sci; 1993 Aug; 690():113-9. PubMed ID: 8368730
    [No Abstract]   [Full Text] [Related]  

  • 29. Human tumour antigens recognized by T-cells: perspectives for new cancer vaccines.
    Van den Eynde B; Gaugler B; van der Bruggen P; Coulie P; Brichard V; Boon T
    Biochem Soc Trans; 1995 Aug; 23(3):681-6. PubMed ID: 8566443
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunological ignorance of silent antigens as an explanation of tumor evasion.
    Chen L
    Immunol Today; 1998 Jan; 19(1):27-30. PubMed ID: 9465485
    [No Abstract]   [Full Text] [Related]  

  • 31. Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.
    Liao X; Li Y; Bonini C; Nair S; Gilboa E; Greenberg PD; Yee C
    Mol Ther; 2004 May; 9(5):757-64. PubMed ID: 15120337
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Induction and functional analysis of cytotoxic T lymphocytes specific for the novel tumor-associated antigen CML66].
    Suemori K
    Rinsho Ketsueki; 2009 Aug; 50(8):604-10. PubMed ID: 19915374
    [No Abstract]   [Full Text] [Related]  

  • 33. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
    Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
    Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [T Lymphocytes with Modified Specificity in the Therapy of Malignant Diseases].
    Vdovin AS; Bykova NA; Efimov GA
    Mol Biol (Mosk); 2017; 51(6):1008-1023. PubMed ID: 29271964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Tumor antigen-specific cytotoxic T lymphocytes and cancer immunotherapy - review].
    Liu Y
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2004 Apr; 12(2):244-8. PubMed ID: 15157343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cytotoxic T-cell immune response against melanoma antigens].
    Ayyoub M
    Ann Dermatol Venereol; 1998 Nov; 125 Suppl 2():S34-6. PubMed ID: 9922891
    [No Abstract]   [Full Text] [Related]  

  • 37. Cotransfection of dendritic cells with RNA coding for HER-2/neu and 4-1BBL increases the induction of tumor antigen specific cytotoxic T lymphocytes.
    Grünebach F; Kayser K; Weck MM; Müller MR; Appel S; Brossart P
    Cancer Gene Ther; 2005 Sep; 12(9):749-56. PubMed ID: 15877082
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53: a potential target antigen for immunotherapy of cancer.
    Offringa R; Vierboom MP; van der Burg SH; Erdile L; Melief CJ
    Ann N Y Acad Sci; 2000 Jun; 910():223-33; discussion 233-6. PubMed ID: 10911916
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of cancer vaccine by tumor rejection antigens.
    Itoh K; Hayashi A; Toh Y; Imai Y; Yamada A; Nishida T; Shichijo S
    Int Rev Immunol; 1997; 14(2-3):153-71. PubMed ID: 9131385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer immunotherapy with mRNA-transfected dendritic cells.
    Gilboa E; Vieweg J
    Immunol Rev; 2004 Jun; 199():251-63. PubMed ID: 15233739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.